ImmunityBio (IBRX) Securities Lawsuit 2026 Are You Part of the Class?

Investors filed a federal securities class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain of its executives after the FDA publicly released a warning letter accusing the company of making false and misleading claims about its cancer drug Anktiva. The lawsuit was filed in the United States District Court for the Central District of California, captioned Douglas v. ImmunityBio, Inc., Case No. 2:26-cv-03261, on behalf of investors who purchased or acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. No settlement exists yet. This is an active, early-stage case.

Quick Facts

Field	Detail
Company (Ticker)	ImmunityBio, Inc. (NASDAQ: IBRX)
Settlement Amount	TBD — No settlement reached
Lead Plaintiff Deadline	May 26, 2026
Class Period	January 19, 2026 – March 24, 2026
Who Qualifies	Investors who purchased or acquired IBRX securities during the class period
Payout Per Person	TBD
Settlement Status	Litigation phase — no settlement proposed
Court	U.S. District Court, Central District of California
Case Number	2:26-cv-03261
Drug at Center of Case	Anktiva® (nogapendekin alfa inbakicept-pmln)

Where the Case Stands Right Now

• The lawsuit is filed in the United States District Court for the Central District of California. Investors have until May 26, 2026, to file for lead plaintiff status.
• Multiple national law firms — including Rosen Law Firm, Pomerantz LLP, Hagens Berman, Levi & Korsinsky, Kessler Topaz Meltzer & Check, and Faruqi & Faruqi — have filed or are investigating related actions. Courts will consolidate these into a single lead case.
• ImmunityBio has acknowledged the FDA warning letter and stated it is reviewing it with legal and regulatory teams. The company has not yet formally responded to the securities lawsuit.

What Is ImmunityBio and What Does Anktiva Do?

ImmunityBio is a California-based biotech company that develops cancer therapies. Its lead product, Anktiva, received FDA approval in 2024 for a specific and narrow use: treating adults with a hard-to-treat form of non-muscle-invasive bladder cancer who have not responded to standard BCG therapy.

ImmunityBio has been working to win FDA approval to expand the drug’s use to a number of other conditions, including forms of lung and pancreatic cancer. The company’s executive chairman, Dr. Patrick Soon-Shiong — a billionaire who also owns the Los Angeles Times — is its most public face and scientific voice.

The lawsuit does not allege the drug itself is harmful or ineffective for its approved use. Instead, it alleges that company executives made false or misleading public statements about the drug’s capabilities, and that those statements inflated the stock price before the truth came out.

What Did ImmunityBio’s Executives Actually Say?

The core of the case involves a podcast appearance and a TV advertisement — both of which the FDA later determined were false and misleading.

On January 19, 2026, a direct-to-consumer podcast titled “Is the FDA BLOCKING Life Saving Cancer Treatments?” aired, featuring Dr. Patrick Soon-Shiong. During the podcast, he said that while Anktiva is approved for bladder cancer, “it actually can treat all cancers.”

The FDA’s Office of Prescription Drug Promotion reviewed the TV ad and podcast and determined they were false or misleading. The FDA’s warning letter states that Anktiva is not approved as a treatment for “all cancers” or lung cancer after failure of checkpoint inhibitors, nor is it approved for any form of cancer prevention.

The FDA also flagged that the podcast referred to Anktiva as a “cancer vaccine” — a characterization the agency specifically rejected. The agency noted that material facts were omitted — notably that Anktiva must be used in combination with a vaccine — and that risks were downplayed in the TV ad and never mentioned at all in the podcast.

This Was Not a First Warning

The FDA’s enforcement action did not come without prior notice to the company, and that context matters to the lawsuit.

The FDA’s Office of Prescription Drug Promotion noted it “is concerned that, despite receiving these previous Untitled Letters, ImmunityBio continues to promote Anktiva in a similarly misleading manner.” One untitled letter issued in early 2026 echoed concerns from a previous September 2025 letter about certain statements on Anktiva’s patient- and clinician-facing websites.

This history is central to what investors allege. They argue that company leadership continued making bullish public statements about Anktiva’s potential while the FDA was already signaling concerns through official correspondence — and that investors had no way of knowing this was happening.

The FDA warning letter was dated March 13, 2026, and addressed to ImmunityBio CEO Richard Adcock. It was made public on March 24, 2026.

Why Did IBRX Stock Crash?

When the FDA warning letter became public on March 24, 2026, the market reacted sharply. The stock fell over 21% on March 24, 2026, erasing nearly $2 billion of the company’s market capitalization.

The complaint alleges that Dr. Patrick Soon-Shiong materially overstated Anktiva’s capabilities, and that as a result, defendants’ statements about ImmunityBio’s business, operations, and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.

In other words: investors allege they bought IBRX stock at artificially inflated prices because company executives were saying things about Anktiva that were not supported by clinical evidence or the drug’s actual FDA approval — and that the stock price fell sharply once the FDA publicly corrected the record.

Related article: Perplexity AI Class Action Lawsuit 2026, Was Your Incognito Mode a Sham? What Users Need to Know

Who Is Eligible to Join This Lawsuit?

This is a securities investor lawsuit, not a patient or consumer case. You may be part of the class if:

• You purchased or acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, both dates inclusive
• You suffered financial losses when the stock price declined after March 24, 2026
• You are not one of the named defendants (ImmunityBio executives or board members named in the complaint)

There is no minimum loss required. All class members who purchased IBRX stock during the class period and lost money are automatically included in any recovery. You do not need to hold the stock today. If you bought during the class period and sold at a loss, you may still qualify.

Lead Plaintiff vs. Class Member — What’s the Difference?

Many investors confuse these two roles. They are very different.

A lead plaintiff is a court-appointed investor (or group of investors) who directs the litigation strategy and works closely with attorneys throughout the case. The lead plaintiff selects the law firm that will represent the entire class and has direct oversight of litigation strategy. Courts evaluate the largest financial interest, but any investor may apply. Serving as lead plaintiff costs nothing out of pocket — attorneys’ fees and litigation expenses are paid only from any recovery, and only after court approval.

A class member participates automatically, without taking any action now. If the case reaches a settlement, class members receive notice through their brokers and have the opportunity to file a claim at that time.

The May 26, 2026 deadline applies only to lead plaintiff applications — not to your right to recover as a class member.

How to Protect Your Rights (Step-by-Step)

Step 1 — Locate your brokerage records showing all IBRX purchases and sales between January 19, 2026 and March 24, 2026.

Step 2 — Calculate your approximate losses: shares purchased × purchase price, minus shares sold × sale price (or current value if still held).

Step 3 — Contact a securities class action law firm for a free consultation. These firms work on contingency — you pay nothing upfront, and attorney fees come only from any recovery.

Step 4 — If you want to apply for lead plaintiff status, your attorney must file a motion with the court before May 26, 2026.

Step 5 — If you are not seeking lead plaintiff status, retain all brokerage records and monitor the case for future settlement notices.

Step 6 — Save all correspondence and confirmation numbers for your records.

Estimated time to complete Steps 1–3: approximately 20–30 minutes.

Important Dates

Milestone	Date
Class Period Begins	January 19, 2026
FDA Warning Letter Dated	March 13, 2026
FDA Warning Letter Made Public	March 24, 2026
Class Period Ends	March 24, 2026
IBRX Stock Drops ~21%	March 24, 2026
Lawsuit Filed	Late March / Early April 2026
Lead Plaintiff Deadline	May 26, 2026
Settlement Proposed	TBD
Final Approval Hearing	TBD
Expected Payment Date	TBD

Frequently Asked Questions

Do I need a lawyer to be part of this class action?

 No. You are automatically included as a class member if you purchased IBRX securities during the class period and lost money. You only need an attorney if you want to apply for lead plaintiff status or if you wish to opt out to pursue an individual lawsuit. Class action attorneys work entirely on contingency — they collect fees only from any recovery, not from you.

Is this lawsuit legitimate?

 Yes. The case is filed in the United States District Court for the Central District of California under Case No. 2:26-cv-03261. The FDA warning letter at the center of the case is a publicly available official government document on the FDA’s own website. Multiple nationally recognized securities litigation firms have independently filed or investigated related actions.

When will I receive any payment? 

There is no payment timeline yet because no settlement has been reached. Securities class actions of this type typically take one to four years to resolve. Once a settlement is reached, the court sets a separate claim-filing deadline and provides notice to class members through their brokerage accounts.

What if I already sold my IBRX shares? 

You may still qualify. Eligibility depends on when you purchased IBRX securities — not whether you currently hold them. If you bought during the class period (January 19 – March 24, 2026) and sold at a loss, you likely still have a valid recognized loss claim. Keep your transaction records.

What if I miss the lead plaintiff deadline? 

Missing the May 26, 2026 lead plaintiff deadline does not remove you from the class. It only means you cannot apply for the role of directing the lawsuit. You remain a class member and preserve your right to receive compensation from any future settlement.

Will a settlement payment affect my taxes?

 Potentially, yes. Payments from securities litigation recoveries are generally treated as a return of capital reduction or a capital gain, depending on how the settlement is structured relative to your individual losses. Consult a tax professional once any settlement is announced, as tax treatment varies by situation.

What law did ImmunityBio allegedly break?

 The complaint alleges that the company and its executives violated federal securities laws by making false and misleading statements and failing to disclose that Dr. Patrick Soon-Shiong materially overstated Anktiva’s capabilities, causing investors’ statements about ImmunityBio’s business, operations, and prospects to be materially false and misleading and to lack a reasonable basis at all relevant times. The specific statutes are Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 — the core federal prohibitions on securities fraud.

What does ImmunityBio say about the lawsuit? 

ImmunityBio has not issued a formal public response to the securities class action. Regarding the FDA warning letter that triggered it, ImmunityBio stated that it takes the FDA’s concerns seriously, has initiated a review with its legal and regulatory teams, and is committed to maintaining the highest standards for scientific accuracy and regulatory compliance. The company has not admitted any wrongdoing.

Sources & References

• FDA Official Warning Letter to ImmunityBio — March 13, 2026

For related coverage on pharmaceutical and biotech securities class actions, see our article on the Celgene $239 million securities class action settlement and the ODDITY Tech (ODD) securities class action lawsuit.

Last Updated: April 5, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice regarding a particular situation, consult a qualified attorney.